Glenmark gets marketing approval for Ryaltris in 13 European countries

Glenmark Pharmaceuticals said that it has secured marketing approval for Ryaltris, a fixed-dose combination nasal spray, in 13 countries across the European Union (EU) and the UK.

Ryaltris (olopatadine 665 µg and mometasone furoate 25 µg) has approval for the symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children, aged over 12.

The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, sneezing, nasal itching, apart from itchy, red and watery eyes.

Glenmark Pharmaceuticals said that it will directly launch Ryaltris in Czech Republic, Poland, the UK, and Slovakia.

In other markets of Europe, the fixed-dose combination nasal spray will be marketed by the Menarini Group under an exclusive licensing agreement with the Indian pharma company.

Robert Crockart — Chief Commercial Officer of Glenmark Pharmaceuticals said: “Allergic rhinitis is both widespread and underreported, making it challenging to diagnose and treat in time. It impacts a person’s quality of life and can lead to functional impairments, while also increasing the risk of asthma. This marketing approval will pave the way for effective and timely treatment of allergic rhinitis for thousands of patients across Europe.

“We are already seeing its therapeutic benefits in other regions where Ryaltris has been launched, and we hope to extend this relief to more people across the world.”

Glenmark Pharmaceuticals has agreements with Hikma Pharmaceuticals and Bausch Health for commercializing Ryaltris in the US and Canada, respectively.

Earlier this month, the Indian pharma company had bagged final approval for Clindamycin Phosphate Foam, 1% from the US Food and Drug Administration (FDA).